SAN FRANCISCO, Aug. 30 /PRNewswire-FirstCall/ -- Osteologix, Inc. (OTC
Bulletin Board: OLGX) a biopharmaceutical company headquartered in San
Francisco, California, and with offices in Copenhagen, Denmark, announced
today that it has been invited to give a presentation at the Roth Capital
Conference in New York City.
The presentation, by Charles J. Casamento, CEO and President of
Osteologix, will be on September 7, 2006 at 12:30 PM eastern time at The
Westin New York Hotel at Times Square. Mr. Casamento will present an
overview of the Company's clinical development program for NB S101, its new
product which is being developed for the treatment of Osteoporosis and will
focus on Osteologix's recent accomplishments as well as upcoming future
milestone events. The presentation will be web cast and will be available
at http://wsw.com/webcast/roth8/osteologix/. It will also be archived for
90 days and can be accessed on the Company's website http://www.osteologix.com .
About Osteologix
Osteologix develops innovative products for the treatment of important
unmet medical needs in bone disease and women's health. The Company's lead
product, NB S101, is entering Phase II clinical trials for the treatment of
Osteoporosis. It is believed that NB S101 may both increase new bone
formation while decreasing bone resorption. No other product currently on
the US market both increases bone formation while decreasing bone
resorption. On May 24, 2006 Osteologix merged with a public shell company
while completing a side by side financing managed by Rodman & Renshaw and
Roth Capital Partners. The company is committed to creating value by
building a world-class team, accelerating the development of lead product
candidates, expanding its pipeline by being the alliance partner of choice,
and nurturing a unique company culture. Additional information on
Osteologix can be obtained on the Company's website, http://www.osteologix.com.
FORWARD-LOOKING STATEMENTS
Certain of the statements set forth in this press release constitute
"Forward looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include, without
limitation, any statement that may predict, forecast, indicate, or imply
future results, performance or achievements, and may contain the words
"estimate," "project," "intend," "forecast," "anticipate," "plan,"
"planning," "expect," "believe," "will," "will likely," "should," "could,"
"would," "may" or words or expressions of similar meaning. All such forward
looking statements involve risks and uncertainties, including, but not
limited to: statements regarding Osteologix's research and development
programs; proposed marketing and sales; patents and regulatory approvals;
the effect of competition and proprietary rights of third parties; the need
for and availability of additional financing and access to capital; the
seeking of joint development, licensing or distribution and collaboration
and marketing arrangements with pharmaceutical companies; and the period of
time for which the proceeds of the offering described above will enable
Osteologix to fund its operations. There can be no assurance that such
forward-looking statements will prove to be accurate and Osteologix
undertakes no obligation to update any forward-looking statements or to
announce revisions to any of the forward-looking statements.
SOURCE Osteologix, Inc.
 back to top
Related links:
http://www.osteologix.com/
CONTACT:
Charles J. Casamento, CEO & President of
Osteologix, Inc., +1-415-955-2726, or ccasamento@osteologix.com
|
